This therapeutic effect stems from the relief of CTLA-4-mediated inhibition, which allows for the reactivation of T-cell proliferation and promotes their differentiation into cytotoxic T lymphocytes (CTLs), enhancing anti-tumor immunity [76,77]. The gene discussed is CTLA4; the disease is neoplasm.